Over the past several decades, significant strides have been made in the development of new treatments for prostate cancer.  Twenty years ago, the only option for patients with metastatic castration-resistant prostate cancer (mCRPC) was to continue androgen deprivation therapy (ADT), despite diminishing efficacy; today, there are over a dozen treatment options and combinations for patients with advanced prostate cancer. These new treatments and the advent of PSA screening have reduced prostate cancer mortality rates by over 50% since 1993; however, an estimated 34,700 patients in the U.S. and 375,000 globally are still dying from prostate cancer each year. 1, 2 Our work is not yet done.